B7 score and T cell infiltration stratify immune status in prostate cancer
Qianghua Zhou,Kaiwen Li,Yiming Lai,Kai Yao,Qiong Wang,Xiangyu Zhan,Shirong Peng,Wenli Cai,Wei Yao,Xingxing Zang,Kewei Xu,Jian Huang,Hai Huang
DOI: https://doi.org/10.1136/jitc-2021-002455
IF: 12.469
2021-08-01
Journal for ImmunoTherapy of Cancer
Abstract:Background Although immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients with prostate cancer (PCa) has been somewhat marginal. This study aimed to assess the feasibility of B7-H3 or HHLA2 as alternative immunotherapeutic targets in PCa. Methods Immunohistochemistry was performed to evaluate the expression pattern of PD-L1, B7-H3 and HHLA2 and the infiltration of CD8 + and Foxp3 + lymphocytes in 239 PCa tissues from two independent cohorts. The correlations between B7-H3 and HHLA2 and clinicopathological features, including the presence of CD8 + and Foxp3 + tumor-infiltrating lymphocytes (TILs), were explored. Results HHLA2 expression was much higher than PD-L1 expression but lower than B7-H3 expression in PCa tissues. High expression of both B7-H3 and HHLA2 was significantly associated with higher Gleason score and tumor stage, lymph node metastasis and dismal overall survival (OS) and cancer-specific survival (CSS). Moreover, a high B7 score, defined as high B7-H3 expression and/or high HHLA2 expression, was an independent prognostic predictor for PCa. Of note, a high B7 score was negatively correlated with CD8 + TILs. Importantly, a new immune classification, based on the B7 score and CD8 + TILs, successfully stratified OS and CSS in PCa. Conclusions Both B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment, and the B7 score could be used as an independent prognostic factor for PCa. The B7 score combined with CD8 + TILs could be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa. These findings may provide insights that could improve response to immune-related comprehensive therapy for PCa in the future.
oncology,immunology